Page 299 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

278 PART III Therapeutic Modalities for the Cancer Patient

236. Hirte H, Vergote IB, Jeffrey JR, et al.: A phase III randomized trial 255. Shaked Y, Kerbel RS: Antiangiogenic strategies on defense: on the
of BAY 12-9566 (tanomastat) as maintenance therapy in patients possibility of blocking rebounds by the tumor vasculature after che-
with advanced ovarian cancer responsive to primary surgery and motherapy, Cancer Res 67:7055–7058, 2007.
VetBooks.ir paclitaxel/platinum containing chemotherapy: a National Cancer 256. Bertolini F, Paul S, Mancuso P, et al.: Maximum tolerable dose
and low-dose metronomic chemotherapy have opposite effects on
Institute of Canada Clinical Trials Group Study, Gynecol Oncol
102:300–308, 2006.
237. Moore MJ, Hamm J, Dancey J, et al.: Comparison of gemcitabine the mobilization and viability of circulating endothelial progenitor
cells, Cancer Res 63:4342–4346, 2003.
versus the matrix metalloproteinase inhibitor BAY 12-9566 in 257. Daenen LG, Shaked Y, Man S, et al.: Low-dose metronomic cyclo-
patients with advanced or metastatic adenocarcinoma of the pan- phosphamide combined with vascular disrupting therapy induces
creas: a phase III trial of the National Cancer Institute of Canada potent antitumor activity in preclinical human tumor xenograft
Clinical Trials Group, J Clin Oncol 21:3296–3302, 2003. models, Mol Cancer Ther 8:2872–2881, 2009.
238. Moore AS, Dernell WS, Ogilvie GK, et al.: Doxorubicin and BAY 258. Shaked Y, Emmenegger U, Man S, et al.: Optimal biologic dose of
12-9566 for the treatment of osteosarcoma in dogs: a randomized, metronomic chemotherapy regimens is associated with maximum
double-blind, placebo-controlled study, J Vet Intern Med 21:783– antiangiogenic activity, Blood 106:3058–3061, 2005.
790, 2007. 259. Toh B, Abastado JP: Myeloid cells: prime drivers of tumor progres-
239. Mohammed SI, Khan KN, Sellers RS, et al.: Expression of cyclo- sion, Oncoimmunology 1:1360–1367, 2012.
oxygenase-1 and 2 in naturally-occurring canine cancer, Prostaglan- 260. Umansky V, Sevko A: Tumor microenvironment and
dins Leukot Essent Fatty Acids 70:479–483, 2004. myeloid-derived suppressor cells, Cancer Microenviron 6:
240. Knapp DW, Richardson RC, Chan TC, et al.: Piroxicam therapy 169–177, 2013.
in 34 dogs with transitional cell carcinoma of the urinary bladder, 261. Finn OJ: Immuno-oncology: understanding the function and dys-
J Vet Intern Med 8:273–278, 1994. function of the immune system in cancer, Ann Oncol 23(Suppl
241. Knapp DW, Richardson RC, Bottoms GD, et al.: Phase I trial of 8):viii6–9, 2012.
piroxicam in 62 dogs bearing naturally occurring tumors, Cancer 262. Penel N, Adenis A, Bocci G: Cyclophosphamide-based metro-
Chemother Pharmacol 29:214–218, 1992. nomic chemotherapy: after 10 years of experience, where do we
242. Mohammed SI, Bennett PF, Craig BA, et al.: Effects of the cyclo- stand and where are we going? Crit Rev Oncol Hematol 82:40–50,
oxygenase inhibitor, piroxicam, on tumor response, apoptosis, and 2012.
angiogenesis in a canine model of human invasive urinary bladder 263. Ghiringhelli F, Menard C, Puig PE, et al.: Metronomic cyclophos-
cancer, Cancer Res 62:356–358, 2002. phamide regimen selectively depletes CD4+CD25+ regulatory T
243. Mohammed SI, Craig BA, Mutsaers AJ, et al.: Effects of the cyclo- cells and restores T and NK effector functions in end stage cancer
oxygenase inhibitor, piroxicam, in combination with chemother- patients, Cancer Immunol Immunother 56:641–648, 2007.
apy on tumor response, apoptosis, and angiogenesis in a canine 264. Kerbel RS, Shaked Y: The potential clinical promise of ‘multimo-
model of human invasive urinary bladder cancer, Mol Cancer Ther dality’ metronomic chemotherapy revealed by preclinical studies of
2:183–188, 2003. metastatic disease, Cancer Lett 400:293–304, 2017.
244. Suvannasankha A, Fausel C, Juliar BE, et al.: Final report of toxic- 265. Salem ML, Al-Khami AA, El-Nagaar SA, et al.: Kinetics of
ity and efficacy of a phase II study of oral cyclophosphamide, tha- rebounding of lymphoid and myeloid cells in mouse peripheral
lidomide, and prednisone for patients with relapsed or refractory blood, spleen and bone marrow after treatment with cyclophospha-
multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21, mide, Cell Immunol 276:67–74, 2012.
Oncologist 12:99–106, 2007. 266. Angulo I, de las Heras FG, Garcia-Bustos JF, et al.: Nitric oxide-
245. Bray JP, Orbell G, Cave N, et al.: Does thalidomide prolong sur- producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells
vival in dogs with splenic haemangiosarcoma? J Small Anim Pract in the spleen of cyclophosphamide-treated mice: implications for
59:85–91, 2018. T-cell responses in immunosuppressed mice, Blood 95:212–220,
246. Finotello R, Henriques J, Sabattini S, et al.: A retrospective analysis 2000.
of chemotherapy switch suggests improved outcome in surgically 267. Noguchi M, Moriya F, Koga N, et al.: A randomized phase II
removed, biologically aggressive canine haemangiosarcoma, Vet clinical trial of personalized peptide vaccination with metronomic
Comp Oncol 15:493–503, 2017. low-dose cyclophosphamide in patients with metastatic castration-
247. Fidler IJ, Ellis LM: Chemotherapeutic drugs—more really is not resistant prostate cancer, Cancer Immunol Immunother 65:151–160,
better, Nat Med 6:500–502, 2000. 2016.
248. Hanahan D, Bergers G, Bergsland E: Less is more, regularly: met- 268. Burton JH, Mitchell L, Thamm DH, et al.: Low-dose cyclo-
ronomic dosing of cytotoxic drugs can target tumor angiogenesis in phosphamide selectively decreases regulatory T cells and inhibits
mice, J Clin Invest 105:1045–1047, 2000. angiogenesis in dogs with soft tissue sarcoma, J Vet Intern Med
249. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic 25:920–926, 2011.
chemotherapy, Nat Rev Cancer 4:423–436, 2004. 269. Mitchell L, Thamm DH, Biller BJ: Clinical and immuno-
250. Pasquier E, Kavallaris M, Andre N: Metronomic chemotherapy: modulatory effects of toceranib combined with low-dose
new rationale for new directions, Nat Rev Clin Oncol 7:455–465, cyclophosphamide in dogs with cancer, J Vet Intern Med 26:
2010. 355–362, 2012.
251. Drevs J, Fakler J, Eisele S, et al.: Antiangiogenic potency of various 270. Nars MS, Kaneno R: Immunomodulatory effects of low dose che-
chemotherapeutic drugs for metronomic chemotherapy, Anticancer motherapy and perspectives of its combination with immunother-
Res 24:1759–1763, 2004. apy, Int J Cancer 132:2471–2478, 2013.
252. Bocci G, Nicolaou KC, Kerbel RS: Protracted low-dose effects on 271. Shurin GV, Tourkova IL, Kaneno R, et al.: Chemotherapeutic
human endothelial cell proliferation and survival in vitro reveal agents in noncytotoxic concentrations increase antigen presenta-
a selective antiangiogenic window for various chemotherapeutic tion by dendritic cells via an IL-12-dependent mechanism, J Immu-
drugs, Cancer Res 62:6938–6943, 2002. nol 183:137–144, 2009.
253. Bocci G, Francia G, Man S, et al.: Thrombospondin 1, a mediator 272. Suzuki E, Kapoor V, Jassar AS, et al.: Gemcitabine selectively elimi-
of the antiangiogenic effects of low-dose metronomic chemother- nates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-
apy, Proc Natl Acad Sci USA 100:12917–12922, 2003. bearing animals and enhances antitumor immune activity, Clin
254. Hamano Y, Sugimoto H, Soubasakos MA, et al.: Thrombospon- Cancer Res 11:6713–6721, 2005.
din-1 associated with tumor microenvironment contributes to low- 273. Zhu Y, Liu N, Xiong SD, et al.: CD4+Foxp3+ regulatory T-cell
dose cyclophosphamide-mediated endothelial cell apoptosis and impairment by paclitaxel is independent of toll-like receptor 4,
tumor growth suppression, Cancer Res 64:1570–1574, 2004. Scand J Immunol 73:301–308, 2011.